Heidenhain Variant of Creutzfeldt-Jakob Disease: Diffusion-Weighted MRI and PET Characteristics

Journal of Neuroimaging

Volumn 14, Issue 1, 2004, Pages 63-66

  Tsuji, Yoshihisa ^a   Kanamori, Hiroshi ^a   Murakami, Gaku ^a   Yokode, Masayuki ^a   Mezaki, Takahiro ^a   Doh Ura, Katsumi ^b   Taniguchi, Ken ^c   Matsubayashi, Kozo ^a   Fukuyama, Hidenao ^a   Kita, Toru ^a   Tanaka, Makoto ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Shoraiso National Hospital   (Japan)

Author keywords

14 3 3 protein; Creutzfeldt Jakob disease; Diffusion weighted MRI; PET; Visual disturbance; Visual evoked potentials

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MEMORY DISORDER; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; VISUAL IMPAIRMENT;

BRAIN; CREUTZFELDT-JAKOB SYNDROME; DIFFUSION MAGNETIC RESONANCE IMAGING; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MIDDLE AGED; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 10744224601     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1177/1051228403258147     Document Type: Article

References (26)

1. Brandel JP, Delasnerie-Laupretre N, Laplanche JL, Hauw JJ, Alperovitch A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology 2000;54:1095-1099.
2. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-930.
3. Staffen W, Trinka E, Iglseder B, Pilz P, Homann N, Ladurner G. Clinical and diagnostic findings in a patient with Creutzfeldt-Jakob disease (type Heidenhain). J Neuroimaging 1997;7:50-54.
4. Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-815.
5. Finkenstaedt M, Szudra A, Zerr I, et al. MR imaging of Creutzfeldt-Jakob disease. Radiology 1996;199:793-798.
6. Na DL, Suh CK, Choi SH, et al. Diffusion-weighted magnetic resonance imaging in probable Creutzfeldt-Jakob disease: a clinical-anatomic correlation. Arch Neurol 1999; 56:951-957.
7. Demaerel P, Heiner L, Robberecht W, Sciot R, Wilms G. Diffusion-weighted MRI in sporadic Creutzfeldt-Jakob disease. Neurology 1999;52:205-208.
8. Schroter A, Zerr I, Henkel K, Tschampa HJ, Finkenstaedt M, Poser S. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol 2000;57: 1751-1757.
9. Jacobs DA, Lesser RL, Mourelatos Z, Galetta SL, Balcer LJ. The Heidenhain variant of Creutzfeldt-Jakob disease: clinical, pathologic, and neuroimaging findings. J Neuroophthalmol 2001;21:99-102.
10. Mittal S, Farmer P, Kalina P, Kingsley PB, Halperin J. Correlation of diffusion-weighted magnetic resonance imaging with neuropathology in Creutzfeldt-Jakob disease. Arch Neurol 2002;59:128-134.
11. Rabinstein AA, Whiteman ML, Shebert RT. Abnormal diffusion-weighted magnetic resonance imaging in Creutzfeldt-Jakob disease following corneal transplantations. Arch Neurol 2002;59:637-639.
12. Eschweiler GW, Wormstall H, Widmann U, Naegele T, Bartels M. Correlation of diffusion-weighted magnetic resonance imaging with neurological deficits in sporadic Creutzfeldt-Jakob Disease. Nervenarzt 2002;73:883-886.
13. de Seze J, Hache JC, Vermersch P, et al. Creutzfeldt-Jakob disease: neurophysiologic visual impairments. Neurology 1998;51:962-967.
14. Kropp S, Schulz-Schaeffer WJ, Finkenstaedt M, et al. The Heidenhain variant of Creutzfeldt-Jakob disease. Arch Neurol 1999;56:55-61.
15. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46: 224-233.
16. Bahn MM, Parchi P. Abnormal diffusion-weighted magnetic resonance images in Creutzfeldt-Jakob disease. Arch Neurol 1999;56:577-583.
17. Grunwald F, Pohl C, Bender H, et al. 18F-fluoro-deoxyglucose-PET and 99mTc-bicisate-SPECT in Creutzfeldt-Jakob disease. Ann Nud Med 1996;10:131-134.
18. Henkel K, Zerr I, Hertel A, et al. Positron emission tomography with [(18)F]FDG in the diagnosis of Creutzfeldt-Jakob disease (CJD). J Neurol 2002;249:699-705.
19. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42:85-94.
20. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358-365.
21. Poser S, Mollenhauer B, Kraubeta A, et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999;122:2345-2351.
22. Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643-649.
23. Haik S, Brandel JP, Sazdovitch V, et al. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease. Neurology 2000;55:1401-1404.
24. Aguglia U, Farnarier G, Regis H, Oliveri RL, Quattrone A. Sensory evoked potentials in Creutzfeldt-Jakob disease. Eur Neurol 1990;30:157-161.
25. Finsterer J, Bancher C, Mamoli B. Giant visually-evoked potentials without myoclonus in the Heidenhain type of Creutzfeld-Jakob disease. J Neurol Sci 1999;167:73-75.
26. Green AJ. Use of 14-3-3 in the diagnosis of Creutzfeldt-Jakob disease. Biochem Soc Trans 2002;30:382-386.